What Do TET2, ASXL1, and ZRSR2 Mean in BPDCN NGS Results?

When you look at the genetic testing section of your pathology report (often called next-generation sequencing, or NGS), seeing a list of mutated genes can be overwhelming. TET2, ASXL1, and ZRSR2 are among the most common genetic mutations found in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) ^[1].

Finding these genes on a report means the laboratory has identified variations in your cells’ DNA. However, having one of these mutations does not automatically change the standard treatments your doctor will recommend ^[2]. Instead, they provide researchers and your care team with biological context about how your disease may have formed.

What Your NGS Result Actually Tells You

A genetic report provides raw data, but your doctor must interpret what that data means for you. Not every mutation listed is actively driving the cancer. When reviewing your results, it helps to understand:

• Variant Classification: Some mutations are known to be “pathogenic” (disease-causing), while others are “variants of uncertain significance” (VUS), meaning it is not yet clear if they impact your health.
• Variant Allele Fraction (VAF): This percentage tells the doctor how many cells in the tested sample carry the mutation.
• Where the Mutation Lives: Blood or bone marrow sequencing alone cannot always confirm if a mutation is only in your BPDCN cells, or if it is also in your normal blood cells or inherited.

How These Mutations May Relate to BPDCN Development

In BPDCN, researchers propose a model where mutations in TET2, ASXL1, and ZRSR2 may act as early, “ancestral” mutations ^[3].

In some patients, these genetic changes occur early in life within bone marrow stem cells, creating a pre-leukemic state known as clonal hematopoiesis ^[4].

• TET2 and ASXL1 are involved in regulating how genetic instructions are turned on or off (DNA methylation and epigenetics).
• ZRSR2 plays a role in pre-mRNA splicing, which is how cells process genetic instructions before making proteins.

Experimental studies suggest that when these genes lose their normal function, certain blood cells may survive longer than they should or expand abnormally ^[5][6]. However, these early mutations alone are usually not enough to cause overt BPDCN. The proposed model suggests that over time, these pre-malignant cells may acquire additional mutations (such as in the NRAS or KRAS genes), which can contribute to disease progression and the development of aggressive BPDCN ^[4][7].

Because they may occur early, TET2, ASXL1, and ZRSR2 mutations are frequently shared between BPDCN tumors and non-malignant bone marrow cells ^[4].

What Do These Mutations Mean for Prognosis?

Prognosis refers to the likely course and outcome of a disease. If you have TET2, ASXL1, or ZRSR2 mutations, here is how they fit into the bigger picture:

• Some Studies Link Multiple Mutations with Outcomes: In specific research cohorts, patients who had three or more total genetic mutations, or mutations in DNA-methylation pathways (which includes TET2), were statistically associated with a shorter overall survival ^[8]. However, these are exploratory, group-level findings. A single TET2, ASXL1, or ZRSR2 mutation is not a validated individual risk calculator, and it cannot predict exactly what will happen to you ^[8]. Your overall health, age, and response to therapy are highly important factors.
• They Can Complicate Remission Testing: Because these mutations may exist in your non-malignant bone marrow cells (clonal hematopoiesis), they might remain detectable on genetic tests even after the BPDCN has been successfully treated and there is no detectable disease by the test used ^[3]. Therefore, if these mutations persist after therapy, it does not automatically mean you have relapsed. To assess true remission, doctors use a combination of highly sensitive tests—such as multiparameter flow cytometry, tissue biopsies, and looking at the cells under a microscope—rather than relying on genetic testing alone ^[9].

Do They Influence Treatment Choices or Clinical Trials?

Currently, the presence of TET2, ASXL1, or ZRSR2 mutations does not change the standard, approved treatment plan for BPDCN ^[2].

Standard therapies, such as the targeted drug tagraxofusp or intensive chemotherapy, are chosen based on your overall health, organ function, and fitness rather than your specific genetic profile. If you achieve a first remission and are eligible, an allogeneic hematopoietic stem cell transplant may be considered ^[10][8]. Transplant decisions are highly individualized and depend on your age, donor availability, prior therapies, and disease status.

There are a few ways these pathways are relevant to research:

• Response to Standard Therapy: One small, exploratory study observed that patients with a specific type of TET2 mutation (a “truncating” or loss-of-function variant) had a shorter or less effective response to tagraxofusp ^[11]. However, this is early research and is not a validated rule to deny or alter treatment ^[11].
• Clinical Trials: Because TET2 and ASXL1 are involved in epigenetics, researchers are actively studying drugs that target these pathways, such as hypomethylating agents (like azacitidine or decitabine) combined with venetoclax ^[12][13]. These experimental therapies are being investigated broadly in BPDCN clinical trials. Trial eligibility usually depends on your treatment history and overall health, rather than requiring you to have one of these specific mutations.